gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Artikel

Artikel empfehlen

Concomitant application of Tumour Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro suggests efficacy benefit

Die gleichzeitige Anwendung von Tumor Treating Fields (TTFields), Temozolomid und Lomustin bei Glioblastomzellen in vitro lässt auf Wirksamkeitsvorteile schließen

Meeting Abstract

Suche in Medline nach

  • Hila Fishman - NovoCure Ltd., Haifa, Israel
  • Roni Monin - NovoCure Ltd., Haifa, Israel
  • Eyal Dor-On - NovoCure Ltd., Haifa, Israel
  • Adi Haber - NovoCure Ltd., Haifa, Israel
  • presenting/speaker Sandra Ehrle - Novocure GmbH, München, Deutschland
  • Moshe Giladi - NovoCure Ltd., Haifa, Israel
  • Uri Weinberg - NovoCure Ltd., Haifa, Israel
  • Yoram Palti - NovoCure Ltd., Haifa, Israel

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocP055

doi: 10.3205/22dgnc367, urn:nbn:de:0183-22dgnc3675

Veröffentlicht: 25. Mai 2022

© 2022 Fishman et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Objective: Treatment for newly diagnosed glioblastoma (ndGBM) includes temozolomide (TMZ) chemotherapy; however, more than half of patients do not show response. Tumor Treating Fields (TTFields) therapy concomitant with maintenance TMZ represents an important advance in treatment of patients with ndGBM and is recommended in various treatment guidelines. Recently, lomustine (CCNU) together with TMZ demonstrated improved overall and progression-free survival following resection and radiochemotherapy in patients with ndGBM and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter. This study investigated the efficacy of concomitant application of TTFields with TMZ and CCNU in GBM cells in vitro.

Methods: Using the inovitro system, GBM cells (U-87 MG and LN229) were treated for 72 h with TTFields at a frequency of 200 kHz and an intensity of 1 V/cm RMS. To examine the efficacy of combining TTFields with TMZ and/or CCNU we measured cell survival, clonogenic potential, overall effect (product of cytotoxicity multiplied with clonogenicity), and apoptosis induction.

Results: Combination of TMZ and TTFields resulted in enhanced cytotoxicity in comparison to each single treatment. The cytotoxic effect we observed when co-applying CCNU with TTFields suggested a synergistic interaction between the two treatment modalities. The clonogenic, overall, and apoptotic effects of TMZ and CCNU were increased as well following co-treatment with TTFields. The triple combination of TTFields with both TMZ and CCNU showed better efficacy than TMZ/CCNU or TTFields alone.

Conclusion: The here presented study suggests potential better efficacy in treating GBM by concomitantly applying TTFields with TMZ/CCNU.